Osteogenic differentiation of preosteoblasts on a hemostatic gelatin sponge.
Bone tissue engineering provides many advantages for repairing skeletal defects. Although many different kinds of biomaterials have been used for bone tissue engineering, safety issues must be considered when using them in a clinical setting. In this study, we examined the effects of using a common clinical item, a hemostatic gelatin sponge, as a scaffold for bone tissue engineering. The use of such a clinically acceptable item may hasten the translational lag from laboratory to clinical studies. We performed both degradation and biocompatibility studies on the hemostatic gelatin sponge, and cultured preosteoblasts within the sponge scaffold to demonstrate its osteogenic differentiation potential. In degradation assays, the gelatin sponge demonstrated good stability after being immersed in PBS for 8 weeks (losing only about 10% of its net weight and about 54% decrease of mechanical strength), but pepsin and collagenases readily biodegraded it. The gelatin sponge demonstrated good biocompatibility to preosteoblasts as demonstrated by MTT assay, confocal microscopy, and scanning electron microscopy. Furthermore, osteogenic differentiation and the migration of preosteoblasts, elevated alkaline phosphatase activity, and in vitro mineralization were observed within the scaffold structure. Each of these results indicates that the hemostatic gelatin sponge is a suitable scaffold for bone tissue engineering.
Institute of Nanoengineering and Microsystems, National Tsing Hua University, Hsinchu City 30013, Taiwan.|Pharmacodynamics Technology Department, Center of Excellence for Drug Development, Biomedical Technology and Device Research Labs, Industrial Technology Research Institute, Hsinchu City 30011, Taiwan.
Zong-Keng
ZK
Kuo
Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan.
Po-Liang
PL
Lai
Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan.
Elsie Khai-Woon
EK
Toh
Institute of Applied Mechanics, National Taiwan University, Taipei City 10617, Taiwan.
Cheng-Hsi
CH
Weng
Pharmacodynamics Technology Department, Center of Excellence for Drug Development, Biomedical Technology and Device Research Labs, Industrial Technology Research Institute, Hsinchu City 30011, Taiwan.
Hsiang-Wen
HW
Tseng
Institute of Applied Mechanics, National Taiwan University, Taipei City 10617, Taiwan.
Pei-Zen
PZ
Chang
Institute of Nanoengineering and Microsystems, National Tsing Hua University, Hsinchu City 30013, Taiwan.
Chih-Chen
CC
Chen
Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu City 30013, Taiwan.
Chao-Min
CM
Cheng
D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D002454:Cell Differentiation; D002460:Cell Line; D049109:Cell Proliferation; D005780:Gelatin / Q000737:chemistry*; D006490:Hemostatics; D051379:Mice; D010006:Osteoblasts / Q000166:cytology* / Q000378:metabolism; D010012:Osteogenesis; D023822:Tissue Engineering / Q000379:methods*; D054457:Tissue Scaffolds / Q000737:chemistry*
D006490:Hemostatics; D005780:Gelatin; D000469:Alkaline Phosphatase